As selective CSF1R inhibitors, such as pexidartinib, were shown to reduce the number of CD14dimCD16+ blood monocytes in patients with glioblastoma [21], this paper explores whether REG, which also inhibits CSF1R, has a similar effect. This evidence concerns the gene CSF1R and glioblastoma.